EVEREST-2: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694 an Autologous Logic-gated Tmod CAR T in Heterozygous HLA-A*02 Adults with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Brief description of study

econditioning lymphodepletion) for different cancers that express mesothelin (MSLN). First, the study team will test it on a small number of patients to see if it has few side effects and if it is effective in treating the cancers. Then, they'll include more patients to check there are few side effects again and see how well it works. If it seems effective with few side effects, they study team will continue testing it on more patients with different types of cancer. The study team will closely watch how the treatment works for each type of cancer. If it doesn't seem to be helping enough for a specific type of cancer, they might not include more patients with that cancer type. All the patients in the second part of the study will get the best dosage found from the first part of the study.


Clinical Study Identifier: s23-01409
ClinicalTrials.gov Identifier: NCT06051695
Principal Investigator: Salman Rafi Punekar.
Other Investigators: Jaime Andres Suarez Londono, Nicole Karich, Elaine Shum, Eileen Zhao, Oscar B Lahoud, Scot Niglio, Jamie M Pavlonnis, Eneil De La Pena, Marissa Hornacek, Kirby Rodriguez, Rafael C Singson, Amanda Marie Ferris, Anna C Hatzinikolaou, Jingmei Hsu, Joshua K Sabari, Mohammad Maher Abdul Hay, Nina Beri, Caitlin Elizabeth Ryan, Rena Kandinova, Jessica Wang, Maureen E Musatto, Kelsey Stocker, Sejal Singh, Laura P. Diaz, Samantha VanMaanen, Keriann M Scavone, Kristen Randolph Jordan, Jamie Robin Nemrow, Kristen Spencer, Chelsea F Curione, Kathleen M Madden, Nancy Chan.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.